tissue disease, or severe liver, lung, renal or haematological disease Capsule dislodging Kramer & Case report 1 patient Inclusion: Index test: into the pyriform Chokhavatia () 44 year old male NA System: Bravo™ wireless capsule system sinus Department of Level: NA Indication: Exclusion: Insertion: not stated Medicine, the History of GORD symptoms, NA Placement: 6 cm above the GOJ Mount Sinai to anti-reflux therapy Medical Center, Comparator: NA New York, New York, USA Chest discomfort Lacy, Chehade & Case series 358 patients (257 females, 101 Inclusion: Index test: Crowell () males) Not stated System: Bravo™ wireless capsule system Section of Mean age: 51 ±14 years Level: IV Exclusion: Insertion: transorally Gastroenterology Predominantly (97%) Caucasian Quality: Q1 Not stated Placement: 6 cm above the GOJ or 5 cm and Hepatology, Indications: above the upper border of the LOS CX (no comparator) Symptoms thought secondary to Duration: 48 hours Medical Center, GORD P2 Comparator: NA Lebanon, New Hampshire, USA Retrosternal Lee et al. () Prospective case 40 patients (27 males and 13 Inclusion: Index test: discomfort series females) Department of Not stated System: Bravo™ wireless capsule system Mucosal lesion Internal Medicine, Age: range 28–83 years Exclusion: Insertion: transorally Foreign-body Department of Level: IV Indications: sensation Not stated Placement: 6 cm above the SCJ Emergency Quality: Q3 Typical heartburn with unsatisfactory Medicine, College Duration: 48 hours response to therapy (15), erosive of Medicine, CX (no Comparator: NA oesophagitis and undergoing National Taiwan comparator) preoperative evaluation (25) University, Taipei, P2 Taiwan Mild discomfort Marchese et al. () Prospective case 40 patients (36 patients had Inclusion: Index test: Severe chest pain successful oesophageal placement of
tissue disease, or severe liver, lung, renal or haematological disease Kramer & Chokhavatia () Department of Medicine, the Mount Sinai Medical Center, New York, New York, USA Case report Level: NA 1 patient 44 year old male Indication: History of GORD symptoms, to anti-reflux therapy Inclusion: NA Exclusion: NA Index test: System: Bravo™ wireless capsule system Insertion: not stated Placement: 6 cm above the GOJ Comparator: NA Capsule dislodging into the pyriform sinus Lacy, Chehade & Crowell () Section of Gastroenterology and Hepatology, Medical Center, Lebanon, New Hampshire, USA Case series Level: IV Quality: Q1 CX (no comparator) P2 358 patients (257 females, 101 males) Mean age: 51 ±14 years Predominantly (97%) Caucasian Indications: Symptoms thought secondary to GORD Inclusion: Not stated Exclusion: Not stated Index test: System: Bravo™ wireless capsule system Insertion: transorally Placement: 6 cm above the GOJ or 5 cm above the upper border of the LOS Duration: 48 hours Comparator: NA Chest discomfort Lee et al. () Department of Internal Medicine, Department of Emergency Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan Prospective case series Level: IV Quality: Q3 CX (no comparator) P2 40 patients (27 males and 13 females) Age: range 28–83 years Indications: Typical heartburn with unsatisfactory response to therapy (15), erosive oesophagitis and undergoing preoperative evaluation (25) Inclusion: Not stated Exclusion: Not stated Index test: System: Bravo™ wireless capsule system Insertion: transorally Placement: 6 cm above the SCJ Duration: 48 hours Comparator: NA Retrosternal discomfort Mucosal lesion Foreign-body sensation Marchese et al. () Prospective case 40 patients (36 patients had successful oesophageal placement of Inclusion: Index test: Mild discomfort Severe chest pain
1203-ContractedAssessmentReport-Catheter-free%20ambulatory%20pH%20test%20for%20GORD%20accessible.docx